Mylan to Appeal Court Decision in Generic Paroxetine Hydrochloride CR Case

Company believes court erred in its decision

PITTSBURGH, Oct. 18 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its motion for a preliminary injunction against GlaxoSmithKline and Apotex pertaining to generic Paxil CR was denied at a hearing today in the U.S. District Court for the District of New Jersey. The company believes that the court erred in its decision and intends to appeal.

Mylan Inc. ranks among the leading generic and specialty pharmaceutical companies in the world and provides products to customers in more than 140 countries and territories. The company maintains one of the industry's broadest and highest quality product portfolios supported by a robust product pipeline; operates one of the world's largest active pharmaceutical ingredient manufacturers; and runs a specialty business focused on respiratory, allergy and psychiatric therapies. For more information, please visit www.mylan.com.

SOURCE Mylan Inc.

Virtual Clinical Trials Summit

Virtual Clinical Trials Summit: The Premier Educational Event Focused on Decentralized Clinical Trials

In this virtual environment, we will look at current and future trends for ongoing virtual trials, diving into the many ways companies can improve patient engagement and trial behavior to enhance retention with a focus on emerging technology and harmonized data access across the clinical trial system.